Payment overview · 2025
General Payments
$217.39
9 reported records · 9 companies
Healthcare provider profile · identity verified
Kelly Evans, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MANCHESTER, KY · NPI 1124107693
Verified facts
What the public records show
CMS Open Payments records show Kelly Evans, D.O. received $217.39 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Linzess by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 273 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.51 | 22.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.00 | 13.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$25.11 | 11.6% | 1 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $22.79 | 10.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $21.17 | 9.7% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.96 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.71 | 9.1% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $15.59 | 7.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $13.55 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $217.39 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $48.51 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| Jornay PM Normalized: jornay pm |
Drug | Collegium Pharmaceutical, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $21.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.71 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
273 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Famotidine | Famotidine | 505 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 481 | 38 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 473 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 378 | 38 |
| Levothyroxine Sodium | Levothyroxine Sodium | 373 | 32 |
| Gabapentin | Gabapentin | 290 | 29 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 283 | 40 |
| Eliquis | Apixaban | 273 | 13 |
| Mirtazapine | Mirtazapine | 273 | 16 |
| Atorvastatin Calcium | Atorvastatin Calcium | 272 | 27 |
| Sertraline Hcl | Sertraline Hcl | 238 | 24 |
| Donepezil Hcl | Donepezil Hcl | 234 | 23 |
| Tradjenta | Linagliptin | 219 | 14 |
| Buspirone Hcl | Buspirone Hcl | 214 | 18 |
| Losartan Potassium | Losartan Potassium | 211 | 25 |
| Memantine Hcl | Memantine Hcl | 174 | 13 |
| Metformin Hcl | Metformin Hcl | 174 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 172 | suppressed |
| Omeprazole | Omeprazole | 169 | 15 |
| Baclofen | Baclofen | 163 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 161 | 23 |
| Furosemide | Furosemide | 147 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 143 | 21 |
| Lisinopril | Lisinopril | 136 | 20 |
| Levetiracetam | Levetiracetam | 133 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 34 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 130 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 129 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 114 | 17 |
| Valsartan | Valsartan | 112 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 101 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 97 | 22 |
| Cefdinir | Cefdinir | 94 | 45 |
| Farxiga | Dapagliflozin Propanediol | 92 | suppressed |
| Carvedilol | Carvedilol | 87 | suppressed |
| Glipizide | Glipizide | 83 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 82 | 29 |
| Allopurinol | Allopurinol | 81 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 76 | suppressed |
| Jardiance | Empagliflozin | 66 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 66 | suppressed |
| Nystatin | Nystatin | 64 | 21 |
| Ranolazine Er | Ranolazine | 61 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 60 | suppressed |
| Lactulose | Lactulose | 59 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 56 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 49 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 48 | 14 |
| Prednisone | Prednisone | 48 | 15 |
| Ramipril | Ramipril | 48 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 14 |
| Divalproex Sodium | Divalproex Sodium | 46 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 45 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 43 | 25 |
| Linzess | Linaclotide | 42 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 42 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Ezetimibe | Ezetimibe | 37 | suppressed |
| Clonazepam | Clonazepam | 36 | suppressed |
| Fluconazole | Fluconazole | 35 | 14 |
| Ozempic | Semaglutide | 35 | suppressed |
| Entresto | Sacubitril/Valsartan | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Nifedipine Er | Nifedipine | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 29 | suppressed |
| Methocarbamol | Methocarbamol | 29 | suppressed |
| Lidocaine | Lidocaine | 27 | suppressed |
| Mupirocin | Mupirocin | 27 | 12 |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 26 | suppressed |
| Diazepam | Diazepam | 25 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Meloxicam | Meloxicam | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | 11 |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Lorazepam | Lorazepam | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Nystop | Nystatin | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Trospium Chloride | Trospium Chloride | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Bacitracin-Polymyxin | Bacitracin/Polymyxin B Sulfate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $217.39 · 9 records | ABBVIE INC. | ABRYSVO, Auvelity, CAPLYTA, COMIRNATY, Cologuard Collection Kit, ENDURANT IIS, ImmunoCAP, Jornay PM, PREVNAR 20, UZEDY, VRAYLAR | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error